Augmentin Xr FDA

Consumer Information (PDR):

Consumer Information (MedFacts):

Consumer Information (Cerner Multum):

Advanced Consumer Information (Micromedex):

Professional Monographs (FDA):

Pharmacy FAQ

What is online pharmacy?

Since about the year 2000, hundreds of pharmacies have begun operating over the internet.
Many such pharmacies are, in some ways, similar to community pharmacies; the primary difference is the method by which the medications are reques... more >>

What does the term "generic" mean? Do generic medications produce the same effect as the brand name medicines do?

The difference between a brand name medicine and a generic one is in the name, shape and in the price. A generic drug is usually called by the name of... more >>

Why are generic medicines so cheap?

Generics are much cheaper than brand-name drugs because generic companies do not have overhead cost such as research and marketing. Most generic drugs are manufactured off-shore and sold online. Since manufacturers do not spend ... more >>

Are generic drugs as reliable as brand name pills?

Generic drugs are tested under the same standards as brand-name drugs. Each generic drug is laboratory tested so that the same amount is absorbed into the body as with brand-name drugs.
The FDA (U.S Food and D... more >>

Generic pills do not look like the brand name medication. The pills have a different name printed on them. Why?

As we have already mentioned that no manufacturer can take out a patent for a chemical agent. Thus generics can have the exactly same active ingredient... more >>

Are generic drugs patented?

No, but having a patent does not make it any more reliable.

... more >>
Buy Augmentin Online
Best Prices on High-Quality Generic Drugs!
No Prescription Needed - Fast Worldwide Delivery!
Generic Augmentin (Amoxicillin And Clavulanate)
Generic Augmentin and Other Antibiotics Medications. Order Augmentin Online Now! Fast Worldwide Delivery!

Augmentin Xr FDA

Augmentin XR

Generic Name: amoxicillin sodium, amoxicillin and clavulanate potassium
Dosage Form: extended-release tablets

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN XR (amoxicillin/clavulanate potassium) and other antibacterial drugs, AUGMENTIN XR should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Augmentin XR Description

Augmentin XR is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin (present as amoxicillin trihydrate and amoxicillin sodium) and the β-lactamase inhibitor clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus 6-aminopenicillanic acid. The amoxicillin trihydrate molecular formula is C16H19N3O5S•3H2O, and the molecular weight is 419.45. Chemically, amoxicillin trihydrate is (2S,5R ,6R)-6-[(R ) - ( - ) - 2 - Amino - 2 - (p - hydroxyphenyl)acetamido] - 3,3 - dimethyl - 7 - oxo - 4 - thia - 1 - azabicyclo[3.2.0]heptane - 2 - carboxylic acid trihydrate and may be represented structurally as:


The amoxicillin sodium molecular formula is C16H18N3NaO5S, and the molecular weight is 387.39. Chemically, amoxicillin sodium is [2S-[2α,5α,6β(S *)]] - 6 - [[Amino(4 - hydroxyphenyl)acetyl]amino] - 3,3 - dimethyl - 7 - oxo - 4 - thia - 1 - azabicyclo[3.2.0]heptane - 2 - carboxylic acid monosodium salt and may be represented structurally as:


Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediatedβ-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C8H8KNO5, and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (Z)-(2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate, and may be represented structurally as:


Inactive Ingredients

Citric acid, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, titanium dioxide, and xanthan gum.

Each tablet of Augmentin XR contains 12.6 mg (0.32 mEq) of potassium and 29.3 mg (1.27 mEq) of sodium.

Augmentin XR - Clinical Pharmacology

Amoxicillin and clavulanate potassium are well absorbed from the gastrointestinal tract after oral administration of Augmentin XR.

Augmentin XR is an extended-release formulation which provides sustained plasma concentrations of amoxicillin. Amoxicillin systemic exposure achieved with Augmentin XR is similar to that produced by the oral administration of equivalent doses of amoxicillin alone. In a study of healthy adult volunteers, the pharmacokinetics of Augmentin XR were compared when administered in a fasted state, at the start of a standardized meal (612 kcal, 89.3 g carb, 24.9 g fat, and 14.0 g protein), or 30 minutes after a high-fat meal. When the systemic exposure to both amoxicillin and clavulanate is taken into consideration, Augmentin XR is optimally administered at the start of a standardized meal. Absorption of amoxicillin is decreased in the fasted state. Augmentin XR is not recommended to be taken with a high-fat meal, because clavulanate absorption is decreased. The pharmacokinetics of the components of Augmentin XR following administration of two Augmentin XR tablets at the start of a standardized meal are presented below.

Table 1. Mean (SD) Pharmacokinetic Parameters for Amoxicillin and Clavulanate Following Oral Administration of Two Augmentin XR Tablets (2,000 mg/125 mg) to Healthy Adult Volunteers (n = 55) Fed a Standardized Meal

Parameter (units)



AUC(0-inf) (mcg•hr/mL)

71.6 (16.5)

5.29 (1.55)

Cmax (mcg/mL)

17.0 (4.0)

2.05 (0.80)

Tmax (hours)*

1.50 (1.00-6.00)

1.03 (0.75-3.00)

T½ (hours)

1.27 (0.20)

1.03 (0.17)

*Median (range).

The half-life of amoxicillin after the oral administration of Augmentin XR is approximately 1.3 hours, and that of clavulanate is approximately 1.0 hour.

Clearance of amoxicillin is predominantly renal, with approximately 60% to 80% of the dose being excreted unchanged in urine, whereas clearance of clavulanate has both a renal (30% to 50%) and a non-renal component.

Concurrent administration of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanate.

In a study of adults, the pharmacokinetics of amoxicillin and clavulanate were not affected by administration of an antacid (MAALOX®), either simultaneously with or 2 hours after Augmentin XR.

Neither component in AUGMENTIN XR is highly protein-bound; clavulanate has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound.

Amoxicillin diffuses readily into most body tissues and fluids, with the exception of the brain and spinal fluid. The results of experiments involving the administration of clavulanic acid to animals suggest that this compound, like amoxicillin, is well distributed in body tissues.


Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Amoxicillin is, however, susceptible to degradation by β-lactamases, and therefore, its spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a β-lactam, structurally related to penicillin, which possesses the ability to inactivate a wide range of β-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated β-lactamases frequently found responsible for transferred drug resistance.

The clavulanic acid component of Augmentin XR protects amoxicillin from degradation by β-lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other β-lactam antibiotics.

Amoxicillin/clavulanic acid has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Aerobic Gram-Positive Microorganisms

Streptococcus pneumoniae (including isolates with penicillin MICs ≤2 mcg/mL)

Staphylococcus aureus (including β-lactamase−producing isolates)

NOTE: Staphylococci which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid.

Aerobic Gram-Negative Microorganisms

Haemophilus influenzae (including β-lactamase−producing isolates)

Moraxella catarrhalis (including β-lactamase−producing isolates)

Haemophilus parainfluenzae (including β-lactamase−producing isolates)

Klebsiella pneumoniae (all known isolates are β-lactamase−producing)

The following in vitro data are available, but their clinical significance is unknown.

At least 90% of the following microorganisms exhibit in vitro minimum inhibitory concentrations (MICs) less than or equal to the susceptible breakpoint for amoxicillin/clavulanic acid.1,2 However, the safety and efficacy of amoxicillin/clavulanic acid in treating infections due to these microorganisms have not been established in adequate and well-controlled trials.

Aerobic Gram-Positive Microorganisms

Streptococcus pyogenes

Anaerobic Microorganisms

Bacteroides fragilis (including β-lactamase−producing isolates)

Fusobacterium nucleatum (including β-lactamase−producing isolates)

Peptostreptococcus magnus

Peptostreptococcus micros

NOTE:S. pyogenes, P. magnus, and P. micros do not produceβ-lactamase, and therefore, are susceptible to amoxicillin alone. Adequate and well-controlled clinical trials have established the effectiveness of amoxicillin alone in treating certain clinical infections due to S. pyogenes.

Susceptibility Test Methods

When available, the clinical microbiology laboratory should provide cumulative results of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

Dilution Technique

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure.1,3 Standardized procedures are based on dilution methods (broth or agar; broth for S. pneumoniae and H.influenzae) or equivalent with standardized inoculum concentration and standardized concentrations of amoxicillin/clavulanate potassium powder.

The recommended dilution pattern utilizes a constant amoxicillin/clavulanate potassium ratio of 2 to 1 in all tubes with varying amounts of amoxicillin. MICs are expressed in terms of the amoxicillin concentration in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid. The MIC values should be interpreted according to criteria provided in Table 2.

Diffusion Technique

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobials. One such standardized technique requires the use of a standardized inoculum concentration.1,4 This procedure uses paper disks impregnated with 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) to test susceptibility of microorganisms to amoxicillin/clavulanate potassium. Disk diffusion zone sizes should be interpreted according to criteria provided in Table 2.

Table 2. Susceptibility Test Result Interpretive Criteria for Amoxicillin/Clavulanate Potassium

Minimum Inhibitory Concentration


Disk Diffusion

(Zone Diameter in mm)








Haemophilus spp.


Not applicable (NA)





Klebsiella pneumoniae





14 to 17


Staphylococcus spp.







Streptococcus pneumoniae





NOTE: Susceptibility of S. pneumoniae should be determined using a 1-mcg oxacillin disk. Isolates with oxacillin zone sizes of ≥20 mm are susceptible to amoxicillin/clavulanate acid. An amoxicillin/clavulanate acid MIC should be determined on isolates of S. pneumoniae with oxacillin zone sizes of ≤19 mm.

NOTE:β-lactamase−negative, ampicillin-resistant H. influenzae isolates must be considered resistant to amoxicillin/clavulanic acid.

A report of S (“Susceptible”) indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of I (“Intermediate”) indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible antimicrobials, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high doses of antimicrobial can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of R (“Resistant”) indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be selected.

Standardized susceptibility test procedures require the use of quality control microorganisms to determine the performance of the test procedures.1,3,4 Standard amoxicillin/clavulanate potassium powder should provide the MIC ranges for the quality control organisms in Table 3. For the disk diffusion technique, the 30 mcg amoxicillin/clavulanate potassium disk should provide the zone diameter ranges for the quality control organisms in Table 3.

Table 3. Acceptable Quality Control Ranges for Amoxicillin/Clavulanate Potassium

Quality Control Organism

Minimum Inhibitory Concentration Range (mcg/mL)

Disk Diffusion

(Zone Diameter Range in mm)

Escherichia coli ATCC®* 35218

(H. influenzae quality control)

4/2 to 16/8

17 to 22

Escherichia coli ATCC 25922

2/1 to 8/4

18 to 24

Haemophilus influenzae ATCC 49247

2/1 to 16/8

15 to 23

Staphylococcus aureus ATCC 29213

0.12/0.06 to 0.5/0.25

Not applicable (NA)

Staphylococcus aureus ATCC 25923


28 to 36

Streptococcus pneumoniae ATCC 49619

0.03/0.015 to 0.12/0.06


*ATCC is a trademark of the American Type Culture Collection.

When using Haemophilus Test Medium (HTM).

Indications and Usage for Augmentin XR

Augmentin XR Extended Release Tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase−producing pathogens (i.e., H. influenzae, M. catarrhalis, H. parainfluenzae, K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs = 2 mcg/mL). AUGMENTIN XR is not indicated for the treatment of infections due to S. pneumoniae with penicillin MICs ≥4 mcg/mL. Data are limited with regard to infections due to S. pneumoniae with penicillin MICs ≥4 mcg/mL (see CLINICAL STUDIES).

Of the common epidemiological risk factors for patients with resistant pneumococcal infections, only age >65 years was studied. Patients with other common risk factors for resistant pneumococcal infections (e.g., alcoholism, immune-suppressive illness, and presence of multiple co-morbid conditions) were not studied.

In patients with community-acquired pneumonia in whom penicillin-resistant S. pneumoniae is suspected, bacteriological studies should be performed to determine the causative organisms and their susceptibility when Augmentin XR is prescribed.

Acute bacterial sinusitis or community-acquired pneumonia due to a penicillin-susceptible strain of S. pneumoniae plus a β-lactamase−producing pathogen can be treated with another AUGMENTIN® (amoxicillin/clavulanate potassium) product containing lower daily doses of amoxicillin (i.e., 500 mg q8h or 875 mg q12h). Acute bacterial sinusitis or community-acquired pneumonia due to S. pneumoniae alone can be treated with amoxicillin.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN XR and other antibacterial drugs, AUGMENTIN XR should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.


Augmentin XR is contraindicated in patients with a history of allergic reactions to any penicillin. It is also contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with treatment with amoxicillin/clavulanate potassium.

Augmentin XR is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min.) and in hemodialysis patients.



Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Augmentin XR, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile. cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile. may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Augmentin XR should be used with caution in patients with evidence of hepatic dysfunction. Hepatic toxicity associated with the use of amoxicillin/clavulanate potassium is usually reversible. On rare occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications (see CONTRAINDICATIONS and ADVERSE REACTIONS—Liver).



While amoxicillin/clavulanate potassium possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable if therapy is for longer than the drug is approved for administration.

A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous skin rash. Thus, ampicillin-class antibiotics should not be administered to patients with mononucleosis.

The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving Pseudomonas spp. or Candida spp.), the drug should be discontinued and/or appropriate therapy instituted.

Prescribing AUGMENTIN XR in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients

Augmentin XR should be taken every 12 hours with a meal or snack to reduce the possibility of gastrointestinal upset. If diarrhea develops and is severe or lasts more than 2 or 3 days, call your doctor.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Patients should be counseled that antibacterial drugs, including AUGMENTIN XR, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When AUGMENTIN XR is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by AUGMENTIN XR or other antibacterial drugs in the future. Discard any unused medicine.

Drug Interactions

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with AUGMENTIN XR may result in increased and prolonged blood levels of amoxicillin. Coadministration of probenecid cannot be recommended.

The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. In controlled clinical trials of Augmentin XR, 25 patients received concomitant allopurinol and Augmentin XR. No rashes were reported in these patients. However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.

In common with other broad-spectrum antibiotics, Augmentin XR may reduce the efficacy of oral contraceptives.

Drug/Laboratory Test Interactions

Oral administration of Augmentin XR will result in high urine concentrations of amoxicillin. High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST®, Benedict’s Solution, or Fehling’s Solution. Since this effect may also occur with amoxicillin and therefore Augmentin XR, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX®) be used.

Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted. This effect may also occur with amoxicillin, and therefore, Augmentin XR.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential. The mutagenic potential of AUGMENTIN was investigated in vitro with an Ames test, a human lymphocyte cytogenetic assay, a yeast test, and a mouse lymphoma forward mutation assay, and in vivo with mouse micronucleus tests and a dominant lethal test. All were negative apart from the in vitro mouse lymphoma assay, where weak activity was found at very high, cytotoxic concentrations. AUGMENTIN at oral doses of up to 1,200 mg/kg/day (1.9 times the maximum human dose of amoxicillin and 15 times the maximum human dose of clavulanate based on body surface area) was found to have no effect on fertility and reproductive performance in rats dosed with a 2:1 ratio formulation of amoxicillin:clavulanate.


Teratogenic Effects

Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given AUGMENTIN at oral doses up to 1,200 mg/kg/day revealed no evidence of harm to the fetus due to AUGMENTIN. In terms of body surface area, the doses in rats were 1.6 times the maximum human oral dose of amoxicillin and 13 times the maximum human dose for clavulanate. For mice, these doses were 0.9 and 7.4 times the maximum human oral dose of amoxicillin and clavulanate, respectively. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery

Oral ampicillin-class antibiotics are generally poorly absorbed during labor. Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions. However, it is not known whether the use of Augmentin XR in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary. In a single study in women with premature rupture of fetal membranes, it was reported that prophylactic treatment with AUGMENTIN may be associated with an increased risk of necrotizing enterocolitis inneonates.

Nursing Mothers

Ampicillin-class antibiotics are excreted in the milk; therefore, caution should be exercised when Augmentin XR is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients younger than 16 years have not been established.

Geriatric Use

Of the total number of subjects in clinical studies of Augmentin XR, 18.4% were 65 years or older and 7.2% were 75 years or older. No overall differences in safety and effectiveness were observed between these subjects and younger subjects, and other clinical experience has not reported differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of dose-dependent toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Each tablet of Augmentin XR contains 29.3 mg (1.27 mEq) of sodium.

Adverse Reactions

In clinical trials, 5,643 patients have been treated with Augmentin XR. The majority of side effects observed in clinical trials were of a mild and transient nature; 2% of patients discontinued therapy because of drug-related side effects. The most frequently reported adverse effects which were suspected or probably drug-related were diarrhea (14.5%), vaginal mycosis (3.3%) nausea (2.1%), and loose stools (1.6%). Augmentin XR had a higher rate of diarrhea which required corrective therapy (3.8% versus 2.6% for AUGMENTIN XR and all comparators, respectively).

The following adverse reactions have been reported for ampicillin-class antibiotics:


Diarrhea, nausea, vomiting, indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS).

Hypersensitivity Reactions

Skin rashes, pruritus, urticaria, angioedema, serum sickness-like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), erythema multiforme (rarely Stevens-Johnson syndrome), acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and an occasional case of exfoliative dermatitis (including toxic epidermal necrolysis) have been reported. Whenever such reactions occur, the drug should be discontinued, unless the opinion of the physician dictates otherwise. Serious and occasional fatal hypersensitivity (anaphylactic) reactions can occur with oral penicillin (see WARNINGS).


A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in patients treated with ampicillin-class antibiotics, but the significance of these findings is unknown. Hepatic dysfunction, including hepatitis and cholestatic jaundice, (see CONTRAINDICATIONS), increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been infrequently reported with AUGMENTIN or Augmentin XR. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. On rare occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications.


Interstitial nephritis and hematuria have been reported rarely. Crystalluria has also been reported.

Hemic and Lymphatic Systems

Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. There have been reports of increased prothrombin time in patients receiving AUGMENTIN and anticoagulant therapy concomitantly.

Central Nervous System

Agitation, anxiety, behavioral changes, confusion, convulsions, dizziness, headache, insomnia, and reversible hyperactivity have been reported rarely.


Tooth discoloration (brown, yellow, or gray staining) has been rarely reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.


Following overdosage, patients have experienced primarily gastrointestinal symptoms including stomach and abdominal pain, vomiting, and diarrhea. Rash, hyperactivity, or drowsiness have also been observed in a small number of patients.

In the case of overdosage, discontinue Augmentin XR, treat symptomatically, and institute supportive measures as required. If the overdosage is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed. A prospective study of 51 pediatric patients at a poison control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying.5

Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin.

Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.

Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of both amoxicillin and clavulanate. Both amoxicillin and clavulanate are removed from the circulation by hemodialysis (see DOSAGE AND ADMINISTRATION).

Augmentin XR Dosage and Administration

Augmentin XR should be taken at the start of a meal to enhance the absorption of amoxicillin and to minimize the potential for gastrointestinal intolerance. Absorption of the amoxicillin component is decreased when Augmentin XR is taken on an empty stomach (see CLINICAL PHARMACOLOGY).

The recommended dose of Augmentin XR is 4,000 mg/250 mg daily according to the following table:




Acute bacterial sinusitis

2 tablets q12h

10 days

Community-acquired pneumonia

2 tablets q12h

7-10 days

Tablets of AUGMENTIN(250 mg or 500 mg) CANNOT be used to provide the same dosages as Augmentin XR Extended Release Tablets. This is because AUGMENTIN XR contains 62.5  mg of clavulanic acid, while the AUGMENTIN 250-mg and 500-mg tablets each contain 125 mg of clavulanic acid. In addition, the Extended Release Tablet provides an extended time course of plasma amoxicillin concentrations compared to immediate-release Tablets. Thus, two AUGMENTIN 500-mg tablets are not equivalent to one Augmentin XR tablet.

Scored Augmentin XR Extended Release Tablets are available for greater convenience for adult patients who have difficulty swallowing. The scored tablet is not intended to reduce the dosage of medication taken; as stated in the table above, the recommended dose of Augmentin XR is two tablets twice a day (q12h).

Renally Impaired Patients

The pharmacokinetics of Augmentin XR have not been studied in patients with renal impairment. Augmentin XR is contraindicated in patients with a creatinine clearance of <30 mL/min. and in hemodialysis patients (see CONTRAINDICATIONS).

Hepatically Impaired Patients

Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals (see WARNINGS).

Pediatric Use

Safety and effectiveness in pediatric patients younger than 16 years have not been established.

Geriatric Use

No dosage adjustment is required for the elderly (see PRECAUTIONS, Geriatric Use).


Augmentin XR Extended Release Tablets

Each white, oval film-coated bilayer scored tablet, debossed with Augmentin XR, contains amoxicillin trihydrate and amoxicillin sodium equivalent to a total of 1,000 mg of amoxicillin and clavulanate potassium equivalent to 62.5 mg of clavulanic acid.

NDC 0029-6096-48

Bottles of 28 (7 day XR pack)

NDC 0029-6096-60

Bottles of 40 (10 day XR pack)


Store tablets at or below 25°C (77°F). Dispense in original container.


Acute Bacterial Sinusitis

Adults with a diagnosis of acute bacterial sinusitis (ABS) were evaluated in 3 clinical studies. In one study, 363 patients were randomized to receive either Augmentin XR 2,000 mg/125 mg orally every 12 hours or levofloxacin 500 mg orally daily for 10 days in a double-blind, multicenter, prospective trial. These patients were clinically and radiologically evaluated at the test of cure (day 17-28) visit. The combined clinical and radiological responses were 83.7% for Augmentin XR and 84.3% for levofloxacin at the test of cure visit in clinically evaluable patients (95% CI for the treatment difference = -9.4, 8.3). The clinical response rates at the test of cure were 87.0% and 88.6%, respectively.

The other 2 trials were non-comparative, multicenter studies designed to assess the bacteriological and clinical efficacy of Augmentin XR (2,000 mg/125 mg orally q12h for 10 days) in the treatment of 2288 patients with ABS. Evaluation timepoints were the same as in the prior study. Patients underwent maxillary sinus puncture for culture prior to receiving study medication. At test of cure, the clinical success rates were 87.5% and 86.6% (intention-to-treat) and 92.5% and 92.1% (per protocol populations).

Patients with acute bacterial sinusitis due to S. pneumoniae with reduced susceptibility to penicillin were accrued through enrollment in these 2 open-label non-comparative clinical trials. Microbiologic eradication rates for key pathogens in these studies are shown in the following table:

Clinical Outcome for ABS

Penicillin MICs of S. pneumoniae Isolates


Clinically Evaluable



95% CI



95% CI

All S. pneumoniae





MIC ≥2.0 mcg/mL



85.5, 99.9



83.3, 99.9

MIC = 2.0 mcg/mL



78.9, 99.9



75.1, 99.9

MIC ≥4.0 mcg/mL§



73.5, 100



71.5, 100

H. influenzae





M. catarrhalis





*n/N = patients with pathogen eradicated or presumed eradicated/total number of patients.

Confidence limits calculated using exact probabilities.

S. pneumoniae strains with penicillin MICs of ≥2 mcg/mL are considered resistant to penicillin.

§Includes one patient each with S. pneumoniae penicillin MICs of 8 and 16 mcg/mL.

Community-Acquired Pneumonia

Four randomized, controlled, double-blind clinical studies and one non-comparative study were conducted in adults with community-acquired pneumonia (CAP). In comparative studies, 904 patients received Augmentin XR at a dose of 2,000 mg/125 mg orally every 12 hours for 7 or 10 days. In the non-comparative study to assess both clinical and bacteriological efficacy, 1,122 patients received Augmentin XR 2,000 mg/125 mg orally every 12 hours for 7 days. In the 4 comparative studies, the combined clinical success rate at test of cure ranged from 86.3% to 94.7% in clinically evaluable patients who received Augmentin XR; in the non-comparative study, the clinical success rate was 85.6%.

Data on the efficacy of Augmentin XR in the treatment of community-acquired pneumonia due to S. pneumoniae with reduced susceptibility to penicillin were accrued from the 4 controlled clinical studies and the 1 non-comparative study. The majority of these cases were accrued from the non-comparative study.

Clinical Outcome for CAP due to S. pneumoniae

Penicillin MICs of S. pneumoniae Isolates


Clinically Evaluable



95% CI



95% CI

All S. pneumoniae





MIC ≥2.0 mcg/mL



69.7, 95.2



79.6, 99.9

MIC = 2.0 mcg/mL



73.0, 99.0



81.5, 100

MIC ≥ 4.0 mcg/mL§



39.0, 94.0



42.1, 99.6

*n/N = patients with pathogen eradicated or presumed eradicated/total number of patients.

Confidence limits calculated using exact probabilities.

S. pneumoniae strains with penicillin MICs of ≥2 mcg/mL are considered resistant to penicillin.

§Includes one patient each with S. pneumoniae penicillin MICs of 8 and 16 mcg/mL in the Intent-To-Treat group only.


In 2 randomized, double-blind, multicenter studies, Augmentin XR (2,000 mg/125 mg orally q12h, n = 577) was compared to AUGMENTIN (875 mg/125 mg orally q12h, n = 570), administered for 7 days for the treatment of community-acquired pneumonia. Adverse events, regardless of relationship to test drug, were reported by 44.4% of patients who received Augmentin XR (versus 46.3% in comparator group). Treatment-related adverse events were reported in 21.7% of patients who received AUGMENTIN XR (versus 21.2% in comparator group); most were mild and transient in nature. Adverse events which led to withdrawal were reported by 2.8% of patients who received Augmentin XR (versus 5.3% in comparator group). In each group, the most frequently reported adverse events were diarrhea (14.4% versus 13.0%, p = 0.47), nausea (3.5 % versus 4.4%), and headache (3.5% versus 3.2%). Only 2 patients (0.3%) who received Augmentin XR and 3 patients (0.5%) in the comparator group withdrew due to diarrhea. Serious adverse events considered suspected or probably related to test drug were reported in 0.3% of patients (versus 0.5% in comparator).


  1. Clinical and Laboratory Standards Institute (CLSI) (formerly the National Committee for Clinical Laboratory Standards). Performance Standards for Antimicrobial Susceptibility Testing − Fifteenth Informational Supplement. CSLI Document M100-S15. CLSI, Wayne, PA, 2005.
  2. Clinical and Laboratory Standards Institute (CLSI) (formerly the National Committee for Clinical Laboratory Standards). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria − Sixth Edition. Approved Standard CSLI Document M11-A6, Vol. 24, No. 2. CLSI, Wayne, PA, 2004.
  3. Clinical and Laboratory Standards Institute (CLSI) (formerly the National Committee for Clinical Laboratory Standards). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically − Sixth Edition. Approved Standard CLSI Document M7-A6, Vol. 23, No. 2. CLSI, Wayne, PA, 2003.
  4. Clinical and Laboratory Standards Institute (CLSI) (formerly the National Committee for Clinical Laboratory Standards). Performance Standards for Antimicrobial Disk Susceptibility Tests − Eighth Edition. Approved Standard CLSI Document M2-A8, Vol. 23, No. 1. CLSI, Wayne, PA, 2003.
  5. Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol 1988;30:66-67.

Augmentin XR and AUGMENTIN are registered trademarks of GlaxoSmithKline.

MAALOX is a registered trademark of Novartis Consumer Health, Inc.


Research Triangle Park, NC 27709

©2006, GlaxoSmithKline. All rights reserved.

December 2006AX:L9
Augmentin XR (amoxicillin sodium, amoxicillin and clavulanate potassium)
Product Code 0029-6096 Dosage Form TABLET, EXTENDED RELEASE
Route Of Administration ORAL DEA Schedule
Name (Active Moiety) Type Strength
amoxicillin sodium (amoxicillin) Active 437.5 MILLIGRAM  In 1 TABLET
amoxicillin (amoxicillin) Active 562.5 MILLIGRAM  In 1 TABLET
clavulanate potassium (clavulanic acid) Active 62.5 MILLIGRAM  In 1 TABLET
citric acid Inactive  
colloidal silicon dioxide Inactive  
hypromellose Inactive  
magnesium stearate Inactive  
microcrystalline cellulose Inactive  
polyethylene glycol Inactive  
sodium starch glycolate Inactive  
titanium dioxide Inactive  
xanthan gum Inactive  
sodium Inactive 29.3 MILLIGRAM  In 1 TABLET
potassium Inactive 12.6 MILLIGRAM  In 1 TABLET
Characteristic Appearance Characteristic Appearance
Color WHITE Score 2
Shape OVAL (oval) Symbol false
Imprint Code AUGMENTIN;XR Coating true
Size 22mm
# NDC Package Description Multilevel Packaging
1 0029-6096-48 28 TABLET In 1 BOTTLE None
2 0029-6096-60 40 TABLET In 1 BOTTLE None

Revised: 03/2007

Professional Monographs (FDA)

Online Pharmacies

Online Pharmacies
Online Generic Pharmacy
ED Pills Online Pharmacy

Medical News

Drugmaker GSK says fined $490 mn in China graft probe

A Chinese court on Friday fined British drugmaker GlaxoSmithKline 3.0 billion yuan ($490 million) following a nearly year-long bribery probe, the company said... more >>
Fri, 19 Sep 2014

Regeneron says allergy drug may be darling of its pipeline

By Ransdell Pierson (Reuters) - Regeneron Pharmaceuticals Inc has quickly become one of the world's biggest biotech companies thanks to its Eylea treatment for macular degeneration, but its little known experimental allergy drug could become equally successful, senior company executives said in interviews. The allergy drug, dupilumab, is meant to treat underlying causes of asthma, eczema and nasal polyps and could transform treatment of those suspected related ailments, the officials say. ..... more >>
Fri, 19 Sep 2014

Docs urge action to stop young drivers’ texting

By Janice Neumann NEW YORK (Reuters Health) - Texting while driving could be contributing to thousands of car crashes, especially among teens, and the American College of Preventive Medicine (ACPM) wants policy makers, doctors and parents to do something about it. Texting by novice drivers raises the chances of an accident almost four-fold, the authors of a new position statement point out. But they say new laws, combined with public education, could help eradicate this unnecessary risk on the roadways. ..... more >>
Fri, 19 Sep 2014

U.S. Congress urged to pass bill to speed development of antibiotics

By Toni Clarke WASHINGTON (Reuters) - Financial incentives and a more flexible regulatory approach are needed to persuade drug companies to develop new antibiotics, drug industry and public health experts told U.S. lawmakers on Friday, though some warned that modifying the drug approval process could jeopardize patient safety. The experts said at a hearing of the U.S. ..... more >>
Fri, 19 Sep 2014

Sierra Leone launches controversial Ebola shutdown

Freetown (AFP) - Sierra Leone launched a nationwide three-day shutdown on Friday to contain the deadly spread of an Ebola epidemic described by the UN Security Council as a threat to world peace... more >>
Fri, 19 Sep 2014

India caps prices of 36 more drugs to improve access: government official

By Aditya Kalra and Zeba Siddiqui NEW DELHI/MUMBAI (Reuters) - India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday. The medicines join a list of 348 drugs deemed essential and that are therefore subject to price caps, covering up to 30 percent of the total medication sold in a country where less than 20 percent of people are covered by health insurance. ..... more >>
Fri, 19 Sep 2014

Scientists see risk of mutant airborne Ebola as remote

By Kate Kelland LONDON, Sept 19 (Reuters) - The Ebola virus raging through West Africa is mutating rapidly as it tears a deadly path through cities, towns and villages, but the genetic changes are for now not giving it the ability to spread more easily. Concern that the virus could gain capability to transmit through the air - creating a nightmare scenario of the disease being able to spread like a flu pandemic, killing millions - was fueled by a top infectious disease expert in the United States. ..... more >>
Fri, 19 Sep 2014

Worst Ebola outbreak on record tests global response

(Reuters) - International agencies and governments are fighting to contain the world's worst Ebola epidemic since the disease was identified in 1976. The fever, which causes external and internal bleeding, has killed at least, 2,630 people in West Africa. Here is a timeline of the main developments in the outbreak: March 22: Guinea confirms that a previously unidentified hemorrhagic fever, which killed over 50 people in its southeastern Forest Region, is Ebola. One study traces the suspected original source to a 2-year-old boy in the town of Gueckedou. ..... more >>
Thu, 18 Sep 2014

White House calls for task force to tackle antibiotic-resistant bugs

By P.J. Huffstutter (Reuters) - The U.S. government will set up a task force and presidential advisory council to tackle the growing threat of antibiotic resistance, setting a Feb. 15 deadline for it to outline specific steps, White House advisers said on Thursday. The secretaries of Defense, Agriculture and Health and Human Services will set up the task force to advise on steps to ensure the remaining medically important antibiotics available to treat humans stay effective and look at their use in animal feed. ..... more >>
Thu, 18 Sep 2014

FDA approves Eli Lilly's injectable diabetes drug

WASHINGTON (AP) — The Food and Drug Administration has approved a new injectable diabetes drug from Eli Lilly and Co. for adults with the most common form of the disease... more >>
Thu, 18 Sep 2014

Ailing Rob Ford urges voters to back brother for Toronto mayor

TORONTO (Reuters) - Toronto Mayor Rob Ford, in his first public remarks since doctors revealed he has cancer, has asked residents of Canada's largest city to vote for his brother Doug, who has replaced him on the ballot in next month's mayoral election. "I'm encouraging my brother to jump into this race wholeheartedly right now," he said in a three-minute audio recording released on Thursday. "Toronto needs Doug Ford as mayor. ..... more >>
Thu, 18 Sep 2014

Vivus' Stendra gets FDA approval for use 15 minutes before sex

(Reuters) - The erectile dysfunction drug Stendra, currently approved by the U.S. Food and Drug Administration for use 30 minutes before sex, has now been approved for use as little as 15 minutes before sex, the drug's developers said on Thursday. Stendra is the first FDA-approved erectile dysfunction drug that can be taken 15 minutes prior to sexual activity. The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc. Pfizer Inc's blockbuster erectile dysfunction drug, Viagra, can be taken about an hour before sex. ..... more >>
Thu, 18 Sep 2014

Bayer hits record high on move to list plastics business

By Ludwig Burger and Georgina Prodhan FRANKFURT (Reuters) - Germany's Bayer plans to list its plastics business on the stock market in a deal that could value the division at about 10 billion euros ($13 billion) and allow the group to focus on its more profitable life-science businesses. News of a spin-off that Chief Executive Marijn Dekkers said will free up money for investment in Bayer's healthcare, veterinary drugs and crop protection businesses, lifted the company's shares to a record high. By 1535 GMT (11.35 a.m. EDT) the shares had gained 6.2 percent to 112.70 euros, outperforming a 0. ..... more >>
Thu, 18 Sep 2014

Secure Italian military lab to grow medical marijuana

By Steve Scherer ROME (Reuters) - Italy said on Thursday it would grow medical marijuana at a secure military lab outside Florence and distribute it through pharmacies to slash costs and make it more easily available to the sick. The use of medical marijuana or cannabis derivatives to treat patients has been legal in Italy since 2007, but only a few dozen people took it through the national healthcare system in 2013 because of its prohibitive cost. ..... more >>
Thu, 18 Sep 2014
Consumer Information MedFacts, Cerner Multum, Micromedex, PDR and Professional Monographs (FDA) © 2007-2011 Augmentin  Augmentin Xr FDA